株式会社フェニックスバイオ

Functional Analysis of Human Hepatocytes Isolated From Chimeric Mouse Liver

Harimoto, N. Nakagawara, H. Shirabe, K. Yoshizumi, T. Itoh, S. Ikegami, T. Soejima, Y. Maehara, Y. Ishida, Y. Tateno, C. Tanaka, Y.

Transplant Proc. 2018 Dec;50(10):3858-3862. doi: 10.1016/j.transproceed.2018.06.035.

READ MORE(PUB MED)

Lack of human relevance for procymidone’s developmental toxicity attributable to species difference in its kinetics and metabolism

Tomigahara, Y. Tarui, H. Matsui, M. Kurosawa, M. Kawamura, S. Isobe, N.

J Pestic Sci. 2018 May 20;43(2):114-123. doi: 10.1584/jpestics.D17-085.

READ MORE(PUB MED)

Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model

Ye, X. Tateno, C. Thi, E. P. Kakuni, M. Snead, N. M. Ishida, Y. Barnard, T. R. Sofia, M. Shimada, T. Lee, A. C. H.

ACS Infect Dis. 2018 Nov 8. doi: 10.1021/acsinfecdis.8b00192.

READ MORE(PUB MED)

ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection

Thi, E. P. Dhillon, A. P. Ardzinski, A. Bidirici-Ertekin, L. Cobarrubias, K. D. Cuconati, A. Kondratowicz, A. S. Kwak, K. Li, A. H. L. Miller, A. Pasetka, C. Pei, L.Phelps, J. R. Snead, N. M. Wang, X. Ye, X. Sofia, M. J. Lee, A. C. H.

ACS Infect Dis. 2018 Nov 19. doi: 10.1021/acsinfecdis.8b00191.

READ MORE(PUB MED)

Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes

Tsuge, M. Hiraga, N. Zhang, Y. Yamashita, M. Sato, O. Oka, N. Shiraishi, K. Izaki, Y. Makokha, G. N. Uchida, T. Kurihara, M. Nomura, M. Tsushima, K. Nakahara, T. Murakami, E. Abe-Chayama, H. Kawaoka, T. Miki, D. Imamura, M. Kawakami, Y. Aikata, H. Ochi, H. Hayes, C. N. Fujita, T. Chayama, K.

Virology. 2018 Sep 18;525:48-61. doi: 10.1016/j.virol.2018.08.020.

READ MORE(PUB MED)

CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients

Nomura, M. Tsuge, M. Uchida, T. Hiraga, N. Kurihara, M. Tsushima, K. Fujino, H. Nakahara, T. Murakami, E. Abe-Chayama, H. Kawaoka, T. Miki, D. Hiramatsu, A. Imamura, M. Kawakami, Y. Aikata, H. Ochi, H. Zhang, Y. Makokha, G. N. Hayes, C. N. Tanaka, S. Chayama, K.

J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12970.

READ MORE(PUB MED)

The metabolic fate of fenclozic acid in chimeric mice with a humanized liver

Ekdahl, A. Weidolf, L. Baginski, M. Morikawa, Y. Thompson, R. A. Wilson, I. D.

Arch Toxicol. 2018 Sep;92(9):2819-2828.

READ MORE(PUB MED)

Contribution of chimeric mice with a humanized liver to the evaluation of pharmacology, toxicity, and pharmacokinetics in drug discovery and development

Sanoh, S. Ohta, S.

Nihon Yakurigaku Zasshi. 2018;151(5):213-220

READ MORE(PUB MED)

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure

Teraoka, Y. Uchida, T. Imamura, M. Hiraga, N. Osawa, M. Kan, H. Saito, Y. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

J Gen Virol. 2018 Jun 19. doi: 10.1099/jgv.0.001091.

READ MORE(PUB MED)

Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers

Furuta, M. Tanaka, H. Shiraishi, Y. Unida, T. mamura, M. Fujimoto, A. Fujita, M. Sasaki-Oku, A. Maejima, K. Nakano, K. Kawakami, Y. Arihiro, K. Aikata, H. Ueno, M. Hayami, S. Ariizumi, S. I. Yamamoto, M. Gotoh, K. Ohdan, H. Yamaue, H. Miyano, S. Chayama, K. Nakagawa, H.

Oncotarget. 2018 May 18;9(38):25075-25088.

READ MORE(PUB MED)

The whole transcriptome effects of the PPARalpha agonist fenofibrate on livers of hepatocyte humanized mice

de la Rosa Rodriguez, M. A. Sugahara, G. Hooiveld, Gjej Ishida, Y. Tateno, C. Kersten, S.

BMC Genomics. 2018 Jun 7;19(1):443. doi: 10.1186/s12864-018-4834-3.

READ MORE(PUB MED)

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

Teraoka, Y. Uchida, T. Imamura, M. Osawa, M. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

Biochem Biophys Res Commun. 2018 Jun 2;500(2):152-157.

READ MORE(PUB MED)

Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug-drug interactions

Takaoka, N. Sanoh, S. Okuda, K. Kotake, Y. Sugahara, G. Yanagi, A. Ishida, Y. Tateno, C. Tayama, Y. Sugihara, K. Kitamura, S. Kurosaki, M. Terao, M. Garattini, E. Ohta, S.

Biochem Pharmacol. 2018 Apr 17;154:28-38.

READ MORE(PUB MED)

FXR Activation by Obeticholic Acid or Non-Steroidal Agonists Induces a Human-Like Lipoprotein Cholesterol Change in Mice with Humanized Chimeric Liver

Papazyan, R. Liu, X. Liu, J. Dong, B. Plummer, E. M. Lewis, R. D., 2nd Roth, J. D. Young, M. A.

J Lipid Res. 2018 Mar 20. pii: jlr.M081935. doi: 10.1194/jlr.M081935.

READ MORE(PUB MED)

Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics

Ishida, Y. Chung, T. L. Imamura, M. Hiraga, N. Sen, S. Yokomichi, H. Tateno, C. Canini, L. Perelson, A. S. Uprichard, S. L. Dahari, H. Chayama, K.

Hepatology. 2018 Mar 23. doi: 10.1002/hep.29891.

READ MORE(PUB MED)

Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection

Rolt, A. Le, D. Hu, Z. Wang, A. Q. Shah, P. Singleton, M. Hughes, E. Dulcey, A. E.He, S. Imamura, M. Uchida, T. Chayama, K. Xu, X. Marugan, J. J. Liang, T. J.

J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093/infdis/jiy039.

READ MORE(PUB MED)

A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage

Reddy, B. U. Mullick, R. Kumar, A. Sharma, G. Bag, P. Roy, C. L. Sudha, G. Tandon, H. Dave, P. Shukla, A. Srinivasan, P. Nandhitha, M.Srinivasan, N. Das, S.

Antiviral Res. 2017 Dec 7;150:47-59.

READ MORE(PUB MED)

Hepatitis C replication inhibitors that target the viral NS4B protein

Miller, J. F. Chong, P. Y. Shotwell, J. B. Catalano, J. G. Tai, V. W. Fang, J. Banka, A. L. Roberts, C. D. Youngman, M. Zhang, H. Xiong, Z. Mathis, A. Pouliot, J. J. Hamatake, R. K. Price, D. J. Seal, J. W., 3rd Stroup, L. L. Creech, K. L. Carballo, L. H. Todd, D. Spaltenstein, A. Furst, S. Hong, Z. Peat, A. J.

J Med Chem. 2014 Mar 13;57(5):2107-20

READ MORE(PUB MED)

Significance of aldehyde oxidase during drug development: Effects on drug metabolism, pharmacokinetics, toxicity, and efficacy

Sanoh, S. Tayama, Y. Sugihara, K. Kitamura, S. Ohta, S.

Drug Metab Pharmacokinet. 2015 Feb;30(1):52-63.

READ MORE(PUB MED)

A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression

Mueller, H. Wildum, S. Luangsay, S. Walther, J. Lopez, A. Tropberger, P. Ottaviani, G. Lu, W. John Parrott, N. Zhang, J. D. Schmucki, R. Racek, T. Hoflack, J. C. Kueng, E. Point, F. Zhou, X. Steiner, G. Lutgehetmann, M. Rapp, G. Volz, T. Dandri, M. Yang, S. Young, J. A. T. Javanbakht, H.

J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32393-0. doi: 10.1016/j.jhep.2017.10.014.

READ MORE(PUB MED)

研究発表

Functional Analysis of Human Hepatocytes Isolated From Chimeric Mouse Liver

Lack of human relevance for procymidone’s developmental toxicity attributable to species difference in its kinetics and metabolism

Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model

ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection

Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes

CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients

The metabolic fate of fenclozic acid in chimeric mice with a humanized liver

Contribution of chimeric mice with a humanized liver to the evaluation of pharmacology, toxicity, and pharmacokinetics in drug discovery and development

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure

Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers

The whole transcriptome effects of the PPARalpha agonist fenofibrate on livers of hepatocyte humanized mice

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug-drug interactions

FXR Activation by Obeticholic Acid or Non-Steroidal Agonists Induces a Human-Like Lipoprotein Cholesterol Change in Mice with Humanized Chimeric Liver

Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics

Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection

A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage

Hepatitis C replication inhibitors that target the viral NS4B protein

Significance of aldehyde oxidase during drug development: Effects on drug metabolism, pharmacokinetics, toxicity, and efficacy

A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression